MPS Pharmaa Ltd

MPS Pharmaa Ltd endured a challenging week, closing down 11.06% from ₹2.08 to ₹1.85, sharply underperforming the Sensex which gained 1.35% over the same period. The steep decline was triggered by a downgrade to a 'Strong Sell' rating by MarketsMOJO on 29 December 2025, reflecting deteriorating fundamentals and bearish technical signals. Despite the broader market's modest gains, MPS Pharmaa's shares hit a new 52-week low and remained subdued throughout the week amid persistent investor concerns.

The next results date for MPS Pharmaa is 14 November 2025.

MPS Pharmaa has experienced a consistent decline in financial performance from 2020 to 2025, with worsening reserves, decreasing shareholder funds, and negative profit before tax in multiple years, indicating ongoing operational and liquidity challenges. The book value per share fell from Rs 4.38 in 2020 to Rs 0.57 in 2025.

MPS Pharmaa has experienced a significant decline in financial performance from 2018 to 2025, with net sales dropping from 4.00 Cr to 0.00 Cr and consistent losses in operating profit and net profit. Total liabilities and assets have also decreased, reflecting a substantial reduction in shareholder value.

MPS Pharmaa has experienced declining shareholder's funds and increasing liabilities, with total reserves worsening from -9.58 crore in March 2019 to -17.14 crore in March 2024, and a decrease in book value per share from Rs 4.99 to Rs 1.03 during the same period. The company reported no profit before tax in March 2024 and has not generated cash flow from operating activities in recent years.

MPS Pharmaa Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on ethical, generic, and over-the-counter drugs. As of September 2024, it reported a net profit of -2 Cr and has a market cap of INR 6 Cr.

The top shareholders of MPS Pharmaa are Omkam Pharmaceuticals Private Limited with 25.65%, Pataliputra International Limited at 17.51%, and individual investors holding a combined 36.05%. There are currently no mutual funds or foreign institutional investors involved.

As of March 2019, the management team of MPS Pharmaa includes Peeyush Kumar Aggarwal (Managing Director), Manoj Kumar Jain and Madhu Sharma (Independent Directors), Pooja Chuni (Company Secretary), and Ram Niwas Sharma (Director). They are responsible for the company's governance and operations.

As of May 27, 2025, MPS Pharmaa shows a mildly bullish trend in daily moving averages, but longer-term indicators like weekly and monthly MACD, KST, and Bollinger Bands suggest a mixed outlook with bearish signals.

As of May 27, 2025, MPS Pharmaa shows a mildly bullish trend in daily moving averages, but longer-term indicators like weekly and monthly MACD, KST, and Bollinger Bands suggest a mixed outlook with bearish signals.

As of November 12, 2024, MPS Pharmaa is considered risky and overvalued with a PE ratio of -5.22 and an EV to EBITDA of -2.59, indicating severe operational challenges and inefficiencies, despite a significant 666.67% return over the past five years, which is unsustainable compared to the Sensex's 211.54% return.